Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced Desmoplastic Melanoma By Ogkologos - September 4, 2025 582 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1512 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June June 5, 2025 As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... February 25, 2021 The EPA’s Limitations On This Toxic Pesticide Put Children At Risk... February 5, 2021 Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients... December 13, 2021 Load more HOT NEWS Longer Duration of Treatment with ICIs Associated with a Higher Rate... Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On... What Are Biosimilars in Cancer Treatment? Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer
